insights_auto
Varför har EVO gått ned 2,74%?
Gå på djupetchevron_right
EVO:NASDAQ
Evotec SE
1,60 US$
arrow_downward
−2,74%(−0,045) 1 d
2 okt., 16:00:01 GMT−4 · USD
search
Alla symboler
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för EVO …
Öppen
1,63 US$
Högt
1,63 US$
Lågt
1,59 US$
Börsvärde
591,76 mn
Genomsn. vol.
125,68 tn
Volym
52,03 tn
52v högst
4,27 US$
52v lägst
1,50 US$
EPS
−0,62 US$
Beta
1,98
Utestående aktier
355,82 mn
Antal anställda
4 tn
Öppen
1,63 US$
Högt
1,63 US$
Lågt
1,59 US$
Börsvärde
591,76 mn
Genomsn. vol.
125,68 tn
Volym
52,03 tn
52v högst
4,27 US$
52v lägst
1,50 US$
EPS
−0,62 US$
Beta
1,98
Utestående aktier
355,82 mn
Antal anställda
4 tn
Nyheter och artiklar
Från webbkällor och nyhetspartner
AD HOC NEWS
·
för 1 dag sedan
Evotec announces science chief change. Evotec stock trades at EUR 2.93 versus EUR 2.93.
AD HOC NEWS
·
för 2 dagar sedan
Evotec stock after-hours at EUR 2.92: minus 4.26 percent
AD HOC NEWS
·
för 2 dagar sedan
Evotec announces science chief exit and Evotec stock falls 3.93 percent
AD HOC NEWS
·
för 3 dagar sedan
Evotec loses science chief. Evotec stock falls 1.28 percent
Profil
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.
The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more.
On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
Om Evotec SE